Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Travere Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Travere Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was $92.70M. For fiscal 2026 it was $37.78M. The highest annual figure on record is $37.78M in fiscal 2026.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | $37.78M | – |
| FY2025 | Dec 31, 2024 | -$237.48M | – |
| FY2024 | Dec 31, 2023 | -$280.02M | – |
| FY2023 | Dec 31, 2022 | -$186.29M | – |
| FY2022 | Dec 31, 2021 | -$14.79M | – |
| FY2021 | Dec 31, 2020 | -$42.74M | – |
| FY2020 | Dec 31, 2019 | -$58.21M | – |
| FY2019 | Dec 31, 2018 | -$24.96M | -437.1% |
| FY2018 | Dec 31, 2017 | $7.40M | – |
| FY2017 | Dec 31, 2016 | -$3.44M | – |
| FY2016 | Dec 31, 2015 | -$1.39M | – |
| FY2015 | Dec 31, 2014 | -$45.85M | – |
| FY2014 | Dec 31, 2013 | -$17.59M | – |
| FY2012 | Feb 29, 2012 | -$49 | – |
| FY2011 | Feb 28, 2011 | -$689 | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $58.07M | +1065.4% |
| Q1 FY2027 | Mar 31, 2026 | -$40.37M | – |
| Q4 FY2026 | Dec 31, 2025 | $60.68M | – |
| Q3 FY2026 | Sep 30, 2025 | $14.32M | – |
| Q2 FY2026 | Jun 30, 2025 | $4.98M | – |
| Q1 FY2026 | Mar 31, 2025 | -$42.19M | – |
| Q4 FY2025 | Dec 31, 2024 | -$35.72M | – |
| Q3 FY2025 | Sep 30, 2024 | -$42.51M | – |
| Q2 FY2025 | Jun 30, 2024 | -$40.24M | – |
| Q1 FY2025 | Mar 31, 2024 | -$119.01M | – |
| Q4 FY2024 | Dec 31, 2023 | -$70.47M | – |
| Q3 FY2024 | Sep 30, 2023 | -$59.13M | – |
| Q2 FY2024 | Jun 30, 2023 | -$69.30M | – |
| Q1 FY2024 | Mar 31, 2023 | -$81.12M | – |
| Q4 FY2023 | Dec 31, 2022 | -$54.64M | – |
| Q3 FY2023 | Sep 30, 2022 | -$39.53M | -223.3% |
| Q2 FY2023 | Jun 30, 2022 | -$36.81M | -666.6% |
| Q1 FY2023 | Mar 31, 2022 | -$55.32M | – |
| Q4 FY2022 | Dec 31, 2021 | -$26.88M | – |
| Q3 FY2022 | Sep 30, 2021 | $32.06M | +376.1% |
| Q2 FY2022 | Jun 30, 2021 | $6.50M | – |
| Q1 FY2022 | Mar 31, 2021 | -$26.47M | – |
| Q4 FY2021 | Dec 31, 2020 | -$13.87M | – |
| Q3 FY2021 | Sep 30, 2020 | $6.74M | – |
| Q2 FY2021 | Jun 30, 2020 | -$6.45M | – |
| Q1 FY2021 | Mar 31, 2020 | -$29.16M | – |
| Q4 FY2020 | Dec 31, 2019 | -$4.49M | – |
| Q3 FY2020 | Sep 30, 2019 | -$14.12M | – |
| Q2 FY2020 | Jun 30, 2019 | -$19.11M | – |
| Q1 FY2020 | Mar 31, 2019 | -$20.49M | – |
| Q4 FY2019 | Dec 31, 2018 | -$3.57M | – |
| Q3 FY2019 | Sep 30, 2018 | -$3.90M | -162.9% |
| Q2 FY2019 | Jun 30, 2018 | -$2.76M | -150.5% |
| Q1 FY2019 | Mar 31, 2018 | -$14.73M | – |
| Q4 FY2018 | Dec 31, 2017 | -$854.00K | – |
| Q3 FY2018 | Sep 30, 2017 | $6.20M | +33.9% |
| Q2 FY2018 | Jun 30, 2017 | $5.47M | – |
| Q1 FY2018 | Mar 31, 2017 | -$3.41M | – |
| Q4 FY2017 | Dec 31, 2016 | -$8.49M | – |
| Q3 FY2017 | Sep 30, 2016 | $4.63M | – |
See a number that looks wrong?